CN115996728A - 利用Rho激酶抑制剂治疗阿尔茨海默病的方法 - Google Patents

利用Rho激酶抑制剂治疗阿尔茨海默病的方法 Download PDF

Info

Publication number
CN115996728A
CN115996728A CN202180043725.7A CN202180043725A CN115996728A CN 115996728 A CN115996728 A CN 115996728A CN 202180043725 A CN202180043725 A CN 202180043725A CN 115996728 A CN115996728 A CN 115996728A
Authority
CN
China
Prior art keywords
patients
fasudil
disease
alzheimer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043725.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·麦卡利斯特
S·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ursa Pharmaceutical Co
Original Assignee
Ursa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursa Pharmaceutical Co filed Critical Ursa Pharmaceutical Co
Publication of CN115996728A publication Critical patent/CN115996728A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180043725.7A 2020-04-23 2021-01-08 利用Rho激酶抑制剂治疗阿尔茨海默病的方法 Pending CN115996728A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014272P 2020-04-23 2020-04-23
US63/014272 2020-04-23
PCT/US2021/012588 WO2021216139A1 (en) 2020-04-23 2021-01-08 Methods of using rho kinase inhibitors to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
CN115996728A true CN115996728A (zh) 2023-04-21

Family

ID=78269840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043725.7A Pending CN115996728A (zh) 2020-04-23 2021-01-08 利用Rho激酶抑制剂治疗阿尔茨海默病的方法

Country Status (7)

Country Link
US (3) US12329761B2 (https=)
EP (1) EP4138842A4 (https=)
JP (2) JP2023523706A (https=)
CN (1) CN115996728A (https=)
CA (1) CA3175183A1 (https=)
MX (1) MX2022012957A (https=)
WO (1) WO2021216139A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
CN115998736B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Y-27632在特异性抑制幻觉作用中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
WO2006094072A2 (en) 2005-03-01 2006-09-08 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
EP2285217A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases
US9980972B2 (en) 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
US9481864B1 (en) * 2015-06-30 2016-11-01 University Of South Florida Conversion of non-neuronal cells into neurons
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
EP4232041A4 (en) 2020-10-22 2024-09-25 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20240423998A1 (en) * 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms

Also Published As

Publication number Publication date
EP4138842A1 (en) 2023-03-01
US20250268911A1 (en) 2025-08-28
MX2022012957A (es) 2022-11-09
JP2026053635A (ja) 2026-03-25
US20230302011A1 (en) 2023-09-28
US12329761B2 (en) 2025-06-17
WO2021216139A1 (en) 2021-10-28
EP4138842A4 (en) 2024-04-24
US20230190765A1 (en) 2023-06-22
CA3175183A1 (en) 2021-10-28
JP2023523706A (ja) 2023-06-07
US11771704B1 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
CN116249532A (zh) 使用Rho激酶抑制剂治疗血管性痴呆的方法
US11666583B2 (en) Methods of treating cortical dementia associated wandering
US20230263806A1 (en) Methods of treating proteinopathies
EP4125910B1 (en) Rho kinase inhibitors for treating frontotemporal dementia
WO2022046158A1 (en) Methods of treating age-related cognitive decline
WO2022046160A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination